Management of carcinoma of the bladder

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 3, 1998, Pages 217-222

  Petrovich, Zbigniew ^a   Baert, Luc ^c   Boyd, Stuart D ^a   Brady, Luther W ^b   D'Hallewin, Marie ^c   Heilmann, Hans Peter ^d   Jakse, Gerhard ^e   Jones, Peter A ^a   Van Der Meijden, Adrian P M ^f   Oyen, Raymond H ^g   Van Poppel, Hein ^c   Rotman, Marvin ^h   Sauer, Rolf ⁱ   Shipley, William U ^j   Skinner, Eila C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f JEROEN BOSCH HOSPITAL   (Netherlands)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^j HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Bladder cancer; Diagnosis; Therapy

Indexed keywords

AROMATIC AMINE; EPIRUBICIN; FLUOROURACIL;

ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CYSTECTOMY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; QUALITY OF LIFE; TOBACCO; TRANSURETHRAL RESECTION;

CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 0031842186     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199806000-00001     Document Type: Article

References (45)

1. Halim A, Hussain I. Bilharzial bladder cancer. In: Javadpour N, ed. Bladder cancer. Vol. 12. Baltimore: Williams and Wilkins, 1984;136-45.
2. Parkin DM, Laara E, Muir CS. Estimates of the world wide frequency of sixteen major cancers. Int J Cancer 1980;41:184-97.
3. Silverberg E. Statistical and epidemiologic data on urologic cancer. Cancer 1987;60:692-7.
4. World Health Organization International Agency for Research on Cancer. Trends in cancer incidence and mortality. Lyon, France: IARC Scientific Publications, No. 121, 1993.
5. Parker SL, Tong T, Bolden S, Wingo P. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
6. Moller Jensen O, Esteve J, Moller H, Renard H. Cancer in the European community and its member states. Eur J Cancer 1990;11/12:1167-75.
7. Ross RK, Paganini-Hill A, Henderson BE. Epidemiology of bladder cancer. In: Skinner DG, Lieskovsky G, eds. Diagnosis and management of genitourinary cancer. Philadelphia: W B Saunders, 1988:23-31.
8. Yu MC, Ross RK. Epidemiology of bladder cancer. In: Petrovich Z, Baert L, Brady LW, eds. Carcinoma of the bladder: innovations in management. Berlin: Springer, 1987:1-13.
9. Sandberg AA, Bridge JA. Techniques in cancer cytogenetics: an overview and update. Cancer Invest 1992;10:163-72.
10. Hopman AHN, Moesken O, Smeets AWGB, Pairnels RPF, Vooijs P, Ramaekers FCS. Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 1991;51:644-51.
11. Ovita M, Suzuki MY, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorhisms using the polymerase chain reaction. Genomics 1989;5:874-9.
12. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbour: Cold Spring Harbor Laboratory, 1989.
13. Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: new correlation between clinical observations and molecular mechanisms. Semin Urol 1993;11:177-92.
14. Tsai YC, Nichols PW, Hiti AL, William Z, Skinner DG, Jones PA. Alleic of chromosome 9, 11, and 17 in human bladder cancer. Cancer Res 1990;50:44-7.
15. Spruck CH, Gonzales-Zalueta M, Shibata A. P16 alterations are more common in tumor cell lines than uncultured tumors. Nature 1994;370:183-4.
16. Simoneau AR, Spruck CH, Gonzales-Zalueta M. Evidence for two suppressor gene loci associated with proximal chromosome 9p to 9q and distal chromosome 9q in bladder cancer and the initial screening for GAS 1 and PTC mutations. Cancer Res 1996;56:5039-43.
17. Habuchi T, Ogawa O, Kakehi Y. Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 1993;53:579-84.
18. Dalbagni G, Presti JC, Reuter VE, et al. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 1993;2:2-4.
19. Esrig D, Spruck CH, Nickols PW. p53 nuclear accumulation correlates with mutations in p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
20. Soini Y, Turpeneenniemi-Hujanen T, Kamel D, et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of urinary bladder correlates with disease progression. J Natl Cancer Inst 1993;85:1029-35.
21. Kurth KH, Dennis L, Sylvester R, et al. Prognostic factors in superficial bladder tumors. In: Soloway MS, ed. Problems in urology: transitional cell malignancy. Philadelphia: J B Lippincott, 1992:471-83.
22. Rozanski TA, Grossman HB. Recent developments in pathophysiology of bladder cancer. AJR Am J Roentgenol 1994; 163:789-92.
23. Lam DL, Van Meijden APM, Akaza H, et al. Intravesical chemo- and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Proceedings of the fourth international bladder cancer consensus conference. J Urol 1995;2(suppl 2):23-5.
24. Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 1994;157:147-51.
25. Holmang S, Hedelin H, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stage Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823-7.
26. Gelber RD, Goldhirsch A. Meta-analysis: the fashion of summing-up evidence. Ann Oncol 1991;2:461-8.
27. Skinner DG, Lieskovsky G. Management of invasive and high-grade bladder cancer. In: Skinner DG, Lieskovsky G, eds. Diagnosis and management of genitourinary cancer. Philadelphia: W B Saunders, 1988:295-312.
28. Lerner SP, Skinner DG, Lieskovsky G. The rationale for en block pelvic lymph node dissection for bladder cancer patients: long term results. J Urol 1993;149:758-65.
29. Sarkis SS, Dalbagni G, Cordon-Cardo C. Nuclear expression of p53 protein in transitional cell bladder carcinoma, a marker of disease progression. J Natl Cancer Inst 1993;85:53-9.
30. Fradet Y, Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Sem Urol 1993;11:145-53.
31. D'Hallewin MA, Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1996;155:475-6.
32. Oosterlinck W, Kurth KH, Schroder F, et al. A prospective EORTC-GU group randomized trial (30863) comparing transurethral resection followed by a single intravesical installation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749-52.
33. Stein JP, Stenzl A, Esrig D, Skinner DG. Lower urinary tract reconstruction following cystectomy in women using the kock ileal reservoir with bilateral ureteroileal urethrostomy: initial clinical experience. J Urol 1994;152:1404-8.
34. Elmajiian DA, Stein JP, Esrig D, Skinner DG. The kock ileal neobladder. updated experience in 295 male patients. J Urol 1996;156:920-5.
35. Shipley WU, Rose MA. Bladder cancer, the selection of patients for treatment of full dose irradiation. Cancer 1985;55:2278-84.
36. Shipley WU, Prout GR, Einstein AB. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987;258:931-5.
37. Marks LB, Shipley WU. Techniques for external irradiation of patients with invasive carcinoma of the urinary bladder. In: Levitt SH, ed. Technologic basis of radiotherapy: practical clinical applications. 2nd ed. Philadelphia: Lea and Febiger, 1992;355-41.
38. Larsen LE, Engenholm SA. The value of 3-dimensional radiotherapy planning in advanced carcinoma of the urinary bladder based on computed tomography. Acta Oncol 1994;33:655-94.
39. Gospodarowicz MK, Quilty PM, Scalliet P, et al. The place of radiation therapy in definitive treatment of bladder cancer. Int J Urol 1995;2:41-8.
40. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of RTOG phase II trial 8802. J Clin Oncol 1996;14:119-26.
41. Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10 year experience. Int J Radiat Oncol Biol Phys 1994;30:261-6.
42. Kachnic LA, Kaufman DS, Griffin PP, Heney NM, Althausen AF, Shipley WU. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15:1022-9.
43. Houssett M, Maulard C, Chretien YC, et al. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150-7.
44. Rotman M, Aziz H, Porazzo M, et al. Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluoruracil infusion. Int J Radiat Oncol Biol Phys 1990;18:1131-4.
45. Van Poppel H, Van Limbergen E, Tan R, Baert L. Longterm results of interstitial radiotherapy for invasive bladder cancer. Proceedings of the Euro-American Conference on Urological Cancer, Athens, Greece 1992:42.